Title
An ELISA immunoassay employing a conserved Leishmania hypothetical protein for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans
Date Issued
01 August 2017
Access level
metadata only access
Resource Type
journal article
Author(s)
Carvalho A.M.R.S.
Costa L.E.
Salles B.C.S.
Santos T.T.O.
Ramos F.F.
Lima M.P.
Silvestre B.T.
Portela Á.S.B.
Roatt B.M.
Silveira J.A.G.
Gonçalves D.U.
Magalhães-Soares D.F.
Duarte M.C.
Menezes-Souza D.
Coelho E.A.F.
Publisher(s)
Academic Press Inc.
Abstract
In the present study, a conserved Leishmania hypothetical protein, namely LiHypA, was evaluated for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans. This protein showed a high amino acid sequence homology between viscerotropic and cutaneotropic Leishmania species. An enzyme-linked immunosorbent assay (ELISA) was developed using the recombinant antigen (rLiHypA), in addition to the A2 protein and two parasite antigenic preparations, which were used as controls. Regarding human diagnosis, results showed that rLiHypA was more sensitive and specific than ELISA-L. braziliensis SLA in detecting both cutaneous or mucosal leishmaniasis patients, but not those from Chagas disease patients or healthy subjects. Regarding canine diagnosis, this recombinant antigen showed higher sensitivity and specificity values, as well as a perfect accuracy to identify asymptomatic and symptomatic visceral leishmaniasis (VL) in dogs, but not those from vaccinated animals or those developing babesiosis, ehrlichiosis, or Chagas disease. However, using the rA2 protein or L. braziliensis SLA as controls, significant cross-reactivity was found when these samples were used, hampering their sensitivity and specificity values for the diagnosis. In this context, LiHypA could be considered a candidate to be evaluated for the serodiagnosis of visceral and tegumentary leishmaniasis in dogs and humans.
Start page
42
End page
48
Volume
318
Language
English
OCDE Knowledge area
Medicina tropical Inmunología
Scopus EID
2-s2.0-85020123379
PubMed ID
Source
Cellular Immunology
ISSN of the container
00088749
Sponsor(s)
Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção This work was supported by grants from Pró-Reitoria de Pesquisa da Universidade Federal de Minas Gerais ( Edital 02/2017 ), Instituto Nacional de Ciência e Tecnologia em Nanobiofarmacêutica (INCT Nano-Biofar), FAPEMIG ( CBB-APQ-00819-12 and CBB-APQ-01778-2014 ) and CNPq ( APQ-482976/2012-8 , APQ-488237/2013-0 , and APQ-467640/2014-9 ). MACF is a grant recipient of FAPEMIG/CAPES. EAFC is a grant recipient of CNPq. The funding agencies were not involved in data analysis or interpretation. We would like to thank patients for participating in this study and providing the blood samples.
Sources of information: Directorio de Producción Científica Scopus